Publications & Talks

Press & News

Shortcuts:2013   2012   2011   2010   2009   2008   2007   2005   2004   2003
Phase II TAC-HFT Trial Shows Excellent Safety Profile, Suggests Efficacy, for Transendocardial Delivery of Two Types of Autologous Cells for Ischemic Heart Failure
Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
BioCardia's Helical Infusion Catheter Completes Case Number 200 with Excellent Safety Profile
Positive Results from Phase 1/2 POSEIDON Trial Demonstrate Donor (Allogeneic) Adult Mesenchymal Stem Cells (MSCs) Utilizing BioCardia Catheter Delivery System Are Similarly Effective as Patients’ Own Stem Cells in Treating Ischemic Heart Failure
Juventas Therapeutics doses first patient in Phase II STOP-HF trial
BioCardia and Juventas Announce Phase II Development Program of JVS-100 delivered with the Helical Infusion System to treat Heart Failure
Two Year Follow up Safety Data on Helical Infusion System reported in December 2011 Issue of EuroIntervention
Featured in Circulation Research: "Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy Functional Recovery and Reverse Remodeling”
BioCardia elects Industry Veteran, Jay M. Moyes, to Board of Directors
BioCardia Announces CE Mark Approval
BioCardia Announces Issuance of Patents Related to Cardiac Regenerative Medicine Using Cell Therapy
University of Miami announces successful completion of safety phase of autologous stem cells in Transendocardial Autologous Cells in Heart Failure Trial (TAC-HFT); sixty patient randomized portion of trial has been initiated
TABMMI Heart Failure Stem Cell Clinical Trial Results Presented; Improvements Sustained at Three Year Follow-up
Novel UM Stem Cell Trial Completes Early Safety Phase
TAC-HFT Stem Cell Trial Treats First Heart Failure Patient
Stem Cell Researchers At UM Enrolling Patients In Heart Failure Study - Catheter Injection System To Be Used
BioCardia and the University of Miami Receive FDA Clearance to Initiate Co-Sponsored Heart Failure Stem Cell Clinical Trial Comparing Two Cell Populations
BioCardia Completes $7.4 Million Private Equity Financing Successful Round Follows Completion of Phase I Clinical Trial Enrollment and Two Year Follow-up Data Publication on First Cohort
BioCardia announces completion of enrollment of TABMMI cardiac stem cell trial
BioCardia announces completion of two year follow-up for patients enrolled in the TABMMI trial
BioCardia announces peer reviewed publication of one year follow-up data for stem cell clinical trial to treat chronic heart disease
BioCardia announces completion of enrollment for Phase I adult stem cell clinical trial to treat chronic heart disease
BioCardia, Inc. and Symphony Medical, Inc. announce a mutually exclusive agreement for development and commercialization of a combination product that combines Symphony Medical's biotherapeutic technology and BioCardia device delivery technology for the treatment of cardiac conduction disorders
BioCardia announces issuance of two patents on biotherapeutic delivery to the heart
BioCardia announces issuance of patents related to cell and gene therapy and drug eluting stents
Thoratec Corporation Announces Equity Investment in Emerging Heart Failure Technology - BioCardia Is Developing Tools for Delivery of Biotherapeutic Compounds to the Heart
Featured in "Convergence and Complexity in Cardiac Regeneration" START UP, April 2004
Featured in "Cardiac Gene Therapy: Combination Products Next Frontier?"